Aroldi A, Graziani G, Mioni G, Cecchettin M, Brancaccio D, Galmozzi C, Surian M, Cantaluppi A, Ponticelli C
Proc Eur Dial Transplant Assoc. 1979;16:571-6.
Forty-six renal hypercalciuric normocalcaemic patients were treated with hydrochlorothiazide (50mg/day) and amiloride (5 mg/day), both to reduce new stone formation and to suppress parathyroid hyperfunction. A reduction of hypercalciuria and suppression of parathyroid hyperactivity were observed in 41 patients, while in the other five patients no evidence of parathyroid suppression was found and hypercalcaemia developed. Four of five patients underwent parathyroidectomy which was followed by a normalisation of biochemical signs of hyperparathyroidism. These results suggest that the appearance of hypercalcaemia in renal hypercalciuric patients during hydrochlorothiazide/amiloride treatment may be of diagnostic value in unmasking pharmacologically non-suppressible normocalcaemic hyperparathyroidism.
46例肾性高钙尿症伴血钙正常的患者接受了氢氯噻嗪(50毫克/天)和氨氯吡咪(5毫克/天)治疗,目的是减少新结石形成并抑制甲状旁腺功能亢进。41例患者出现高钙尿症减轻和甲状旁腺功能亢进受到抑制,而另外5例患者未发现甲状旁腺受抑制的证据,且出现了高钙血症。5例患者中有4例接受了甲状旁腺切除术,术后甲状旁腺功能亢进的生化指标恢复正常。这些结果表明,在氢氯噻嗪/氨氯吡咪治疗期间,肾性高钙尿症患者出现高钙血症可能对揭示药物不可抑制的血钙正常的甲状旁腺功能亢进具有诊断价值。